Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-01
ICR Author
Marsden,
Author
Popat, S
Hughes, L
O'Brien, M
Ahmad, T
Lewanski, C
Dernedde, U
Jankowska, P
Mulatero, C
Shah, R
Hicks, J
Geldart, T
Cominos, M
Gray, G
Spicer, J
Bell, K
Ngai, Y
Hackshaw, A
Show allShow less
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/1430
DOI
https://doi.org/10.1016/j.jtho.2016.11.1713
Collections
  • Other ICR Research
Language
eng
License start date
2017-01
Citation
Journal of Thoracic Oncology, 2017, 12 (1), pp. S1215 - S1216
Publisher
Elsevier BV

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.